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Summary
We have studied potential regulatory interactions between mature B lymphocyte populations
by analysis of C.B-17 severe combined immunodeficient (SCID) mice reconstituted simultaneously
with immunoglobulin allotype-congenic mixtures of spleen (SP) and peritoneal cavity (PerC)
B cells. We have previously shown that the independent transfer of B cells from these sources
leads to the long-term survival of donor B cells and reconstitution of immunoglobulin levels
in SCID mice (Riggs, J.E., D.L. Robertson, R.S. Stowers, and D.E. Mosier, manuscript submitted
for publication). SP and PerC B cells differ in numerous respects, with the PerC having higher
proportions of large, activated B cells that express the IgM>IgD phenotype and greater numbers
ofCD5 B cells. The injection of equal numbers of B cells from SP and PerC into SCID recipients
(e.g., BALB/c SP + C.B-17 Per C - SCID) has led to the following observations: (a) serum
IgM allotypes in B cell chimeras revealed strict dominance by the allotype contributed by the
PerC B cells; (b) this dominance was not due to regulatory T cells; (c) B cells of the unexpressed
(i.e., SP) allotype were present in the chimera in the spleen but not the peritoneal cavity; and
(d) immunization with TI and TD antigens failed to elicit the SP IgM allotype, whereas secondary
TD antigen immunization elicited low levels of the SP IgG2a allotype. Additional experiments
demonstrated concurrent expression of IgM allotypes derived from both SP and PerC B cells
in recipients that: (a) received a 10-fold excess of SP B cells; (b) received SP B cells before PerC
B cell transfer; or (c) received SP B cells intravenously and PerC B cells intraperitoneally. We
conclude that the establishment of IgM synthesis by PerC B cells leads to a feedback inhibition
of subsequent IgM synthesis by SP B cells, and that the frequency of B cells that can lead to
this effect is substantially higher in peritoneal cavity than in spleen. These data provide further
confirmation of regulatory interactions between B cells in the absence of T lymphocytes (18),
but confound the interpretation of experiments supporting the existence of a separate CD5+
B cell lineage (9) .
lymphocytes isolated from adult mice show evidence of
heterogeneity in a large number offunctional and pheno-
typic assays (1-11). These observations give rise to three ques-
tions: (a) are distinct functions associated with distinct B cell
subsets; (b) do distinct lineages of B cell development exist
(e.g., in a sense analogous to T cells expressing a/(3 or y/S
receptors); and (c) do different B cell subsets (or lineages)
influence each other? Historically, these questions first fo-
cused on B cells responsive to thymus-dependent (TD)1
versus thymus-independent (TI) antigens (1), then on B cells
expressing or not expressing Lyb-5 (12), and the current can-
1Abbreviations used in this paper.' HRP, horseradish peroxidase; PC,
phosphorylcholine; PerC, peritoneal cavity; PVC, polyvinylchloride;
SP, spleen; TD, thymus-dependent; TI, thymus-independent.
didates of conventional B cells and CD5 (Ly-1)-positive B
cells (8). Characterization of peritoneal cavity (PerC) CD5+
B cells has provided the following evidence in support of their
being a distinct B cell subpopulation/lineage. These cellsex-
hibit a specific array of cell surface antigens [CD5+/ - , Mac-
1 + , IgM>IgD, 132201- (7, 8)], express unique V genes
(13), have a distinct s1g+ progenitor (9), and display unique
functional properties such as spontaneous Ig secretion (8),
responsiveness to "environmental"antigens (8, 14), unrespon-
siveness to TD antigens (15), and autoantibody production
(7, 15). However, controversy exists as to the stability of the
CD5+ phenotype, as evidence accumulates that this marker
is also an activation antigen (7, 8, 16, 17). Precursors of
CD5+ B cells in adult animals appear to exist in the PerC
but not the bone marrow (9), which is the clearest argument
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J.E., D.L. Robertson, R.S. Stowers, and D.E. Mosier, manu-
script submitted for publication) described the survival and
function of mature B cells from different lymphoid organs
when transferred to C.B-17scid (SCID) mice, and documented
engraftment ofboth conventional B cells and large, high slgM,
Mac-1 + B cells that are identical to or closely related to the
CD5+ (or their CD5' "sisters") population. The engraft-
ment of the latter population was seen with transfer of all
B cell sources studied, including bone marrow from aged
animals. This paper focuses on the interaction of allotype-
marked B cells derived from spleen (SP) and from PerC when
both are cotransferred to SCID recipients.
Our results extend recent experiments (18) suggesting feed-
back inhibition of Ig synthesis by CD5-like B cells derived
from the PerC. We find that the Ig allotype derived from
PerC B cells dominates over the allotype associatedwith trans-
ferred SP B cells. This allotype dominance is not dependent
upon T cells, and appears to interfere with Ig synthesis rather
than B cell survival. B cells capable of mediating feedback
suppression existboth in the spleen and PerC; they are simply
more frequent in the latter site. These studies have implica-
tions for the issue of separate B cell lineages as well as for
regulatory interactions among B cells.
Materials and Methods
Mice.
￿
BALB/c (H-2d, Igh') and BALB.xid (XID), C.B-17
(H-2d, Ighb), and C.B-17-scid (hereafter, SCID) mice, bred and main-
tained at the Medical Biology Institute (MBI), were used between
8 and 12 wk of age. All donors were age- and sex-matched for es-
tablishing chimeras. All mice were handled in accord with National
InstitutesofHealth (NIH) guidelines. The MBI SCID colony was
derived from breeding pairs kindly provided by Ken Dorschkind,
UC Riverside. As 10% of SCID mice "break through" and pro-
duce Ig, all mice were bled at 8 wk of age and only those mice
with <5 14g/ml of serum IgM were used in these studies.
CellPreparations andAdoptive Transfer.
￿
SP suspensions were pre-
pared by gently mincing spleens between two sterile glass slides
in HBSS. PerC cells were harvested by flushing the peritoneum
with 10 ml HBSS. T cells were depleted by antiThy-1.2 plus com-
plement treatment. Unless specified otherwise, a total of 10 x 106
cells in a volume of 0.2 mls of HBSS (5 x 106 of each allotype)
were injected intravenously into the lateral tail vein or intraper-
itoneally into SCID recipients.
Antigens and Immunizations.
￿
0.3 ml (ti101 organisms) of a
heat-killed Streptococcus pneumoniae (strain R36a, obtained from
American Type Culture Collection [ATCC1, Rockville, MD) prep-
aration and 100 kg of cr(1 --i 3) dextran (Dextran, B1355S) in sa-
line, generously provided by the laboratoryofDr. Roy Riblet (MBI),
were simultaneously injected intraperitoneally with 100 wg KLH.
(Calbiochem-Behring Corp., La Jolla, CA) in saline mixed with
CFA (H37Ra; Difco Laboratories, Detroit, MI), or 50 Etg phos-
phorylcholine (PC)-substituted KLH, prepared as described (19)
and mixedwith IFA (Sigma Chemical Co., St. Louis, MO), were
injected intraperitoneally.
Allotype- and Antigen-specific ELISA.
￿
Allotype-specific serum
IgM levels were determined by ELISA employing flexible poly-
vinylchloride (PVC) plates (Dynatech Laboratories, Alexandria, VA)
coated with an appropriate dilution of affinity-purified rabbit
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anti-mouse IgM antibody. Serial twofold dilutions of test sera and
the standard HPCM2 (IgM', «) for IgM' or total serum IgM de-
tection, or C.B-17 sera for IgMb detection were applied in dupli-
cate to the plates. Total IgM or Ig levels were determined using
an appropriate dilution of rabbit anti-mouse Ig F(ab')a-specific
horseradish peroxidase (HRP) conjugate (Jackson ImmunoResearch
Laboratories, Inc., Avondale, PA). IgM' and IgMb levels were de-
termined, respectively, with biotinylated (20), protein A-purified
(Pierce ImmunoPure IgG purification kit; Pierce Chemical Co.,
Rockford, IL) DS-1 (mouse IgGI anti-IgM' [211) generously
provided by Dr. Donna Sieckmann (NMRI, Bethesda, MD), and
AFS-78.25 (mouse IgG, anti-IgMb (221) mAbs at appropriate di-
lutions. Biotinylated mouse anti-mouse IgG2a' (clone 8.3; [231),
purchased from Pharmingen, La Jolla, CA, was used to detect
IgG2a' anti-KLH antibodies. Streptavidin-HRPO (Fisher Biotech)
was used to detect binding of the biotinylated mAbs. Antigen-
specific ELISAs were conducted in a similar manner. PVC plates
were coated with KLH, or PC-substituted BSA, prepared as de-
scribed (19), or dextran-substituted BSA, the latter generously
provided by Dr. Gary Gilmore (MBI). HPCM2 and MOPC-104E
(IgM, X) served as IgM anti-PC and IgM anti-Dextran standards.
PC-specific antibodies were detected with the rabbit anti-mouse
Ig F(ab')z-specific HR.P conjugate described above. Dextran-spe-
cific antibodieswere detected with an appropriate dilution of goat
anti-mouse X alkaline-phosphataseconjugate (Fisher Biotech), with
phenolphthalein monophosphate serving as the substrate. Calcula-
tions of all Ig levels were done by comparison to standard curves
using a minimum of 5 data points with correlation coefficients
>0.95.
Flow Cytometric Analyses.
￿
SP "or PerC cells were treated with
Tris-buffered NH4C1 to lyse red blood cells. 106 cells were then in-
cubated with various airfuged (100,000g for 10 min) antibody prepa-
rations. T cells were detected with fluoresceinated antiThy-1.2
obtained from Becton Dickenson Immunocytometry Systems,
Mountain View, CA. Total IgM* cells were detected with fluor-
esceinated goat anti-mouse IgM antibody (Fisher Biotech). Sequen-
tial incubations, first with biotinylated, protein A-purified DS-1
or AFS-78.25 followed by avidin-FITC (Fisher Biotech) were used
to detect IgM' or IgMb bearing cells. An appropriate dilution of
biotinylated AF6-122 (mouse IgG, anti-IgD" [22), Pharmingen)
followed by streptavidin-FITC (Fisher), or a saturatingamount of
AMS 9.1.1.1 (mouse IgG2b anti-IgD' [221) tissue culture super-
natant followed by a predetermined amount of fluoresceinated goat
anti-mouse IgG2b (Fisher Biotech) were used to detect IgD allo-
types. Each step was conducted on ice for 30 min with extensive
washing between steps. All samples included propidium iodide to
allow exclusion of dead cells from the analyses. A minimum of 3
x 104 cells were then analyzed on a Coulter EPICS 753 flow
cytometer.
Results
IgM Produced by PerC B Cells Dominates after Co-transfer
of Allotype-Congenic SP and PerC to SCID Mice. We have
previously shown that PerC B cells restore serum Ig levels
in SCID recipients more rapidly than do SP B cells (Riggs,
J.E., et al., manuscript submitted for publication). Given this
result, it is ofinterest to determine if the simultaneous intra-
venous transfer ofmixtures of SP and PerC cells leads to par-
tial or total dominance ofIg produced by the PerC cells. We
used transfers of Ig-allotype marked cell populations to per-
form these co-transfer experiments. All combinations of SPand PerC cells from C.B-17 (Ighb) and BALB/c (Igha)
donors were transferred to SCID mice. The recipients were
bled weekly after intravenous transfer of cells, and their sera
were assayed by ELISA for levels of total IgM, IgM°, and
IgMb. The results of a representative experiment are pre-
sented in Table 1. The co-transfer ofcells from the same tissue
source (e.g., SP' + SPb) led to almost equal representation
ofeach IgM allotype in the serum ofthe SCID chimera. How-
ever, the co-transfer of SP and PerC cells led to dominance
by IgM expressing the allotype ofthe PerC donor. This dom-
inance was stable as it persisted in mice for at least 60 wk
after cell transfer (not shown) .
T Cells Are Not Responsiblefor the Dominance ofthe PerC
Allotype. Dominance of the PerC-contributed allotype in
PerC + SP chimeras could be the result of regulatory T cell
influences (24) . To test this possibility, SP and PerC prepara-
tions were treated with antiThy-1.2 plus complement to de-
plete T cells before co-transfer to SCID recipients. Table 2
illustrates that T cell depletion did not alter the dominance
of the IgM allotype contributed by the PerC B cells. The
completeness of T cell depletion was confirmed by experi-
ments in which SCID recipients ofT cell-depleted mixtures
of PerC and SP were killed at weekly intervals and tested
for the presence of T cells by PHA responsiveness and flow
cytometric analyses. In no instance was there any evidence
of T cells by both criteria for at least 6 wk after transfer (data
not shown). As a further test of the hypothesis that the dom-
inance exerted by PerC cells was attributable to B cells and
not T cells, we used BALB.xid mice as PerC B cell donors.
xid mice have an intrinsic B cell defect manifest at several
levels, including reduced serum IgM levels (6), but their T
cells are normal in most respects (25) . Equal numbers (5 x
106) of B cells from BALB.xid PerC and C.B-17 SP were in-
jected intravenously into SCID recipients. The results shown
in Table 3 demonstrate that the IgMb allotype contributed
by the C.B-17 SP B cells dominated, in contrast to the result
Table 1 .
￿
Co-Transfer of PerC SP B Cells Demonstrates the
Dominance ofPerC B Cells
Serum IgM levels determined 2 wk after transfer by ELISA as out-
lined in Materials and Methods . Analogous results are noted 40 wk
after transfer.
Three recipients per group.
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Table 2 .
￿
T Cell Depletion of Donor Populations Does Not
Alter PerC B Cell Dominance
" Serum IgM levels determined 2 wk after transfer by ELISA as out-
lined in Materials and Methods.
Three recipients per group.
5 All donor populations consisted of <2% Thy-1.2+ cells after T
cell depletion.
when PerC cells from normal donors were used. These data
strongly imply that the allotype dominance exerted by normal
PerC cells is due to B cells and not T cells.
Allotype-speck Staining ofB Cells Shows the Presence ofthe
"Suppressed" B Cells, as well as Predominance ofSP B Cells in
Recipient SP and PerC B Cells in Recipient PerC. Allotype-
specific staining of IgM on B cells and subsequent flow cyto-
metric analysis was conducted to determine if B cells con-
tributed by both PerC and SP persisted in PerC + SP chimeras,
and if so, the location of B cells bearing the SP and PerC
Table 3.
￿
Failure of BALB.xid PerC to Dominate in
CTih CB7 P o-ransfer wt-1
80
Serum IgM levels determined by ELISA 2 wk after transfer.
# Three recipients/group; equal numbers of B cells (5 x 106), deter-
mined by flow cytometry, were transferred.
SCID recipients# of:
Serum IgM levels"
Total IgM Igm, IgMb
#g/ml
Total
SP' + PerCb 871 ± 97 <5 762 ± 71
PerC' + SPb 1,052 ± 285 514 ± 164 <5
T cell-depleteds
SP' + PerCb 625 ± 149 <5 270 ± 75
PerC' + SPb 996 ± 228 464 ± 82 <5
BALB/c control 928 524 <5
C.B-17 control 918 <5 STD
Serum IgM levels"
SCID recipients# of: Total IgM Igm, Igm, Serum IgM levels'
SCID recipients# of: Total IgM Igm, IgMb
Pg/ml
SP' + SPb 353 ± 135 122 ± 14 140 ± 12
,ug/ml
PerC' + PerC11 1,082 ± 239 565 ± 33 750 ± 20 PerC`dW + SPb 266 ± 38 26 ± 17 193 ±
PerC' + SPb 1,351 ± 178 584 ± 90 <5 PerC"'d(') 54 ± 8 ND ND
SP' + PerCb 1,080 ± 201 <5 1,131 ± 27
BALB/c control 1,000 600 <5 BALB.xid control 290 114 <5
C.B-17 control 1,534 <5 STD BALB/c control 882 895 <5
C.B-17 control 1,084 <5 STDN J J 1L U
Z W W J a w
A
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Vallotypes. Table 4 lists the number ofspleen and PerC B cells
expressing membrane IgM', IgD', IgMb, or IgDb, in PerCb
+ SP' recipients, and Fig. 1 illustrates representative staining
profiles from which the data in Table 4 were derived. Splenic
B cells from PerCb + SP' allotype chimeras predominately
expressed mIgM and mIgD of the SP donor allotype (Table
4; Fig. 1, A, E, C, G), although some B cells expressed
IgMb and thus were derived from the PerC donor. In con-
trast, PerC B cells from the same mice had a relative predom-
inance of IgMb cells derived from the PerC donor (Table 4;
Fig. 1 I and K vs. J and L). B cells recovered from the PerC
expressed too little mIgD to be reliably analyzed with the
allotype-specific anti-IgD reagents. Analogous results were
obtained in 10 separate experiments using this as well as the
reciprocal (PerC' + SPb) combination of B cells and by
analyzing recipients 3-40 wk after transfer. These data lead
to two conclusions: (a) that B cells derived from the SP donor
persist even though IgM derived from them is not detected
in the serum; and (b) that B cells bearing the donor SP allo-
type predominate in the spleen ofSCID recipients and those
bearing the donor PerC allotype predominate in the perito-
neal cavity.
Thymus-independent Immunization Fails to Rescue the Sup-
pressed SPA llotype. Having demonstrated the presence of
donor SP B cellsin PerC + SP - SCID mice, we attempted
to promote the secretion of antibody of the SP allotype by
Table 4.
￿
Staining ofSpleen and Peritoneal Cells from SP/PerC
SCID Chimeras
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' Number of cells expressing specific markers determined by mul-
tiplying percent positive cells (determined by subtraction from
appropriate staining controls) by the number of viable cells (deter-
mined by Trypan blue exclusion) .
t SCID recipient of 5 x 106 BALB/c spleen cells (SPI) + 5 x 106
C.B-17 peritoneal cells (PerCb) i.v. 5 wk before being killed.
S NT, Not tested; too few cells were recovered for analyses; No
cells recovered from C.B-17-scid control peritoneal cavity.
deliberate immunization. SCID recipients of PerCb + SP'
B cells were immunized 10 wk after transfer with R36a (S.
pneumoniae) to elicit anti-PC antibodies and with dextran
B1355S to elicit anti-ca (1 - 3) dextran antibodies. Igh'
mice respond to dextran, while Ighb mice do not (26). Use
of allotype-specific reagents to develop antigen-specific ELISAs
permits assessment of the contribution of each donor allo-
type in the response to PC. The results in Table 5 show that
SP' + SPb and PerC' + PerCb recipients had relatively equal
representation ofeach allotype in theirIgM anti-PC response.
In contrast, both the PerC' + SPb and the PerCb + SP'
recipients showed relative dominance of PC antibodies con-
tributed by the PerC B cell donor. Table 5 also illustrates that
PerCb + SP' mice failed to respond to dextran immuniza-
tion with antibody levels greater than the C.B-17 control,
while all other combinations ofB cellsin the SCID chimeras
produce good antidextran responses. Thus, immunization with
TI antigens either fails to elicit antibody production by the
"suppressed" B cellsof splenic origin, as is the case with dex-
tran immunization, or generates only a meager response from
such cells, as seen with PC immunization.
Primary TD Immunization Fails to Rescue SP IgM Allotype
Expression. It is possible that the use of TI antigens leads
to the selective activation of B cell subpopulations (8, 14).
Accordingly, we also tested the ability ofTD antigens to rescue
the "suppressed" SP allotype. PerC + SP (not Tdepleted)
chimeras, BALB/c, C.B-17, and unreconstituted SCID con-
trolswere primed with 100 pg KLH 4 wk after transfer and
boosted with 50 ,ug PC-KLH 4 wk later. The augmented
primary antibody response to PC and the secondary antibody
response to KLH were assayed 7 d after immunization. The
primary IgM response to PC is restrictedto the IgM bearing
the PerC allotype (Table 6). Similar results were obtained for
primary immune sera after KLH and SRBC immunization
(data not shown) . As these mice were carrier-primed to en-
hance T cell help for the primary anti-PC response, we also
tested their secondary IgM' and IgMb anti-KLH response.
While the secondary response to KLH was quite low in these
animals, the IgM allotype contributed by PerC cells appear
to predominate although a small amount of the SP IgM allo-
type was now detectable. Furthermore, when the IgG2a' re-
sponse to KLH was measured, a better antibody response
was seen and the SP allotype was readily detectable. Com-
parison between groups suggests that the major part of this
response came from B cells derived from the SP donor. These
data suggest that the PerC IgM allotype is predominant in
both primary and secondary responses to TD antigens, yet
the SP IgG2a allotype is elicited in a secondary TD response.
This result suggests that the "suppressed" B cell is present
and indicates that it can be activated by antigen under appro-
priate circumstances.
Secondary Transfer to SCID RecipientsFails to Rescue the "Sup-
pressed" SP Allotype We performed secondary transfer experi-
ments to address two issues: (a) how stable is the suppres-
sion of SP B mediated by PerC B; and (b) do all the cells
capable ofmaintaining suppression exist in the spleen of the
primary SCID recipient, or might transfer of cells from the
Group IgM
Number of cells ( x 106)
that Stain Positive for"
IgM' IgMb IgD' IgDb
Spleen cells from:
BALB/c control 62.4 38.5 1.8 52.5 23.4
C.B-17 control 84.2 9.5 29.1 3 .1 69.2
C.B-17 scid control 1.8 3.9 1.5 2.1 2.7
PerCb + SP'-'SCID$ 47.3 39.2 11.5 24.7 13.9
PerCb + SP-SCCDt 46 .3 40.1 13.4 24.3 13.0
Peritoneal cells from:
BALB/c control 7.6 5.1 0.2 NTS NT
C.B-17 control 5 .4 0.1 4.2 NT NT
PerCb + SP'-SCID 3.2 0.5 1 .4 NT NTTable 5.
￿
Thymus-independent Immunization Fails to Rescue the SP Allotype
peritoneal cavity be required to maintain suppression. We pre-
pared SP cells from primary recipients of allotype-disparate
PerC and SP B cells and injected these cells into secondary
SCID recipients. The dominance of theoriginal PerC donor
allotype was maintained following secondary transfer (Table
7). PerC allotype dominancein secondary recipients wasstable
as similar results were observed at 30 wk after transfer. Sec-
Table 6.
￿
Thymus-dependent Immunization Fails to Rescue the
SP IgM Allotype, but Reveals the SP IgG2a Alloqpe
Percent control response'
PerCb + SP' PerC' + SPb
Allotype/antigen tested
￿
recipientst
￿
recipients
" Percent control response determined by comparison with response
generated in appropriate intact allotype controls: BALB/c or C.B-17
mice (n = 3). No response detectable in unreconstituted SCID
controls.
t Allotype controls and SCID recipients (n = 3), reconstituted with
5 x 106 each SPb and PerCa, were immunized intraperitoneally 4
wk after transfer with 100 ug KLH/CFA. Mice were boosted 4 wk
later with 50 ttg PC-KLH/IFA, bled, and assayed 7 d later as
described in Materials and Methods.
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SCID recipients (n = 3) of 5 x 106 cells of each type were immunized 10 wk after transfer.
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ondary transfers conducted40 wk after establishing primary
recipients also failed to rescue the SP allotype (data notshown).
These data indicate that B cell-dependent allotype suppres-
sion is long-lasting and that the spleen contains all the cells
necessary to maintain the PerC B cell dominance established
in the primary SCID recipient.
A 9:1 SP to PerC B Cell Ratio Results in Dominance of the
Allotype ofthe SP Donor. All oftheabove experiments were
performed with equal numbers of PerC and SP B cells in-
jected into SCID recipients. To ask if there were B cells in
the SP that could exert the allotype dominance effect, T
cell-depleted PerC and SP were prepared from allotype-
congenic donors, combined in variousratios, and transferred
to SCID mice. The results (Table 8) demonstrate that a 9:1
SP- to -PerC B cell ratio at the time of transfer resulted in
dominance of the IgM allotype of the SP donor. Both 3:1,
10
(Per C'+SPb)SP--CID
￿
393 ± 75
￿
206 ± 15
￿
<5
BALB/c control
￿
722
￿
465
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<5
C.B-17 control
￿
1,111
￿
<5
￿
STD
" Serum IgM levels determined by ELISA as outlined in Materials
and Methods.
t Donors bled and killed 6 wk after transfer.
S Secondary recipients bled 2 wk after transfer.
Serum
Phosphorylcholine
antibody levels"
SCID recipients# of: Total IgM IgM' IgMb Dextran
hg/ml
SP' + SP, 433 ± 76 283 + 17 238 ± 85 84 + 4
PerC' + PerCb 852 ± 195 655 ± 216 1,102 ± 498 61 ± 3
PerC' + SPb 239 ± 56 184±48 61±6 170±70
SP' + PerCb 256 ± 55 34±6 248±49 11±3
BALB/c control 361 ± 82 500 ± 16 <5 156 ± 10
C.B-17 control 324 ± 16 47±6 252±68 15±2
Primary response:
Table 7. Secondary Transfer Fails to Rescue the SP Allotype
IgM° a PC 36 0
IgMb a PC 0 39 Serum IgM levels"
Total Ig a PC 32 36
SCID recipients of: Total IgM IgM' IgMb
Secondary response:
IgM' a KLH 7 2 (IUg/ml)
IgMb a KLH 1 12 Per Cb + SP' (donor) 608 <5 397
Total Ig a KLH 5 7 (Per C +SP')SP-SCIDS 179 ± 43 <5 154 ±
IgG2a' a KLH 8 19 Per C' +SPb (donor) 938 560 <5" Serum IgM levels determined 2 wk after transfer by ELISA as out-
lined in Materials and Methods.
t Two recipients per group.
s A total of 10 x 106 cells were transferred to each recipient.
II Transfer of 106 Per C alone results in >100 ug/ml serum IgM by
2 wk.
and as shown previously, 1:1 ratios ofB cells resulted in dom-
inance ofthe PerC allotype, although the 3:1 recipients have
detectable levels of the SP allotype. SP B cell dominance is
maintained in these recipients 40 wk after transfer (data not
shown). These data indicate that some resident splenic B cells
are capable of mediating allotype dominance over PerC B cells,
yet the cells necessary for this dominance must be present
in the spleen at a lower frequency than in the peritoneal cavity.
Lack ofAllotype Dominance in SCID Recipients ofLarge SP
and Large PerC B Cells. Previous experiments demonstrated
that PerC B cells most rapidly restored B cell function in
SCID mice (Riggs, J.E., et al., manuscript submitted for pub-
lication). However, transfer oflarge (Percoll gradient selected)
SP B cells resulted in reconstitution kinetics identical to large
PerC B cell recipients. Thus, co-transfer of equal numbers
of density-fractionated, large PerC and SP B cells may lead
to expression of both allotypes. The results in Table 9 show
that this is the case; equal representation of both allotypes
is detected in recipients of equal numbers of large PerC and
SP B cells. These data confirm that the spleen harbors B cells
capable of competing with PerC B cells and suggest that the
SP B cells that mediate this dominance are enriched in a large
B cell fraction.
Sequential Transfer ofPerC B Cells to SCID Mice Previously
Reconstituted with SP B Cells Results in Co-expression ofBoth
A1lotypes. The results presented above indicate that differ-
ences in rates of B cell growth or Ig secretion may explain
PerC B cell dominance in PerC + SP chimeras. To test this
hypothesis, sequential transfers were conducted in which SCID
recipients of SP B cells received PerC B cells 5 wk later. This
sequential transfer protocol should result in the establishment
of B cells from the initial source, effectively negating growth
rate differences, which permits an assessment of the ability
of the second B cell source to compete with the established
primary graft. Table 10 illustrates results for experiments in
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12
' Serum IgM levels determined 10 wk after transfer by ELISA.
t Three recipients/group.
S Large B cells isolated on Percoll gradients as previously described
(11); 2 x 106 cells of each type were injected intravenously.
which SP and PerC B cells are compared for their ability to
establish IgM synthesis in SCID mice previously engrafted
with SP B cells. Prior transfer of SP' B cells precluded sub-
sequent reconstitution of IgMb production by SPb B cells,
indicating again that B cells from SP can mediate allotype
suppression. However, those same animals allowed establish-
ment of IgMb synthesis by PerCb B cells. Equal representa-
tion ofboth allotypes was evident in such chimeras, suggesting
that differences in B cell growth rates alone are not sufficient
to explain PerC B cell dominance. The data in Table 10 also
show that prior injection of PerC B cellsof one allotype pre-
vents expression of the IgM allotype of PerC B cells injected
subsequently. These results suggest that the allotype domi-
nance established by transfer ofPerC B cells is more effective
than that established by SP B cell transfer.
Injection RouteInfluences B Cell-mediatedAllotype Dominance
Early after Transfer. Our previous studies have shown that
intraperitoneal transfer reduced the marked differences in IgM
and B cell reconstitution ratesnoted after intravenous transfer
of SP and PerC B cells (Riggs, J.E., et al., manuscript sub-
mitted for publication) . In addition, the above results (e.g.,
Table 7) led to the question of whether the majority of the
B cellsmediating allotype dominance ended up in the spleen
versus the PerC of SCID recipients. To address these issues,
PerC' and SPb cells were co-transferred in all possible com-
binations ofintravenous and intraperitoneal routes. The data
in Table 11 demonstrate that transient allotype dominance
mediated by the SP donor was evident in recipients of SPb
intravenously and PerC' intraperitoneally at 2 wk after trans-
fer, but not at 10 wk after transfer. All other combinations
of injection routes led to allotype dominance by the PerC
donor. These results suggest that the PerC of the recipient
is not the only or primary site of residence of the B cells
responsible for allotype suppression, and further suggest that
the mechanism of suppression may require relatively close
proximity of the B cells mediating suppression and those being
suppressed.
Table 8. Increasing the
SP Dominance
SP/PerC B Cell Ratio Results in Table 9. Lack of
Large SP and Large PerC
Dominance in SCID
B Cells
Recipients of
SCID recipientst of SPb Serum IgM levels' Serum IgM levels"
+ PerC' at a ratio
(SP/PerC)s of. Total IgM IgM' IgMb SCID recipientst of: Total IgM IgM' IgMb
,ug/ml Pg/ml
9:111 366 ± 22 <5 185 ± 64 Larges SP' +Large
3:1 571±7 573±63 49±9 PerCb 946 ± 90 132 ± 7 198 ±
1 :1 735 ± 98 781 ± 150 <5
BALB/c control 528 339 <5
BALB/c control 859 464 <5 C.B-17 control 986 <5 STD
C.B-17 control 569 <5 STDTable 10.
￿
PerC or SP B Cell Engraftment in SCID Mice Previously Reconstituted with SP or PerC B Cells
' Serum IgM levels determined as described in Materials and Methods.
t Primary recipients reconstituted 5 wk previously with 5 x 106 PerC; all primary recipients expressed only the donor allotype when tested
the day of the second transfer.
Discussion
The transfer ofmature B lymphocyte populations to SCID
recipients allows a detailed analysis of their survival, func-
tion, and interaction in the absence of endogenous T and
B lymphocytes. This is particularly true if B cells or their
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'Serum IgM levels determined by ELISA as outlined in Materials and Methods.
t Three recipients per group; each recipient receiving 5 x 106 each of SP' and Per C'.
S Weeks after transfer.
Peritoneal Cavity B Cell Dominance in SCID Recipients
Serum levels'
products influence the subsequent development or function
of other B cells, as has recently been observed in transfers
of CD5+ B cells to neonatal animals (18), and is well
documentedby the data presented in this paper. The transfer
ofcells to SCID mice has some potential pitfalls as well; e.g.,
Group
Primary SP' recipientst that receive:
5 x 106 SPb
Total IgM
831
IgM'
'Ug/ml
723
IgMb
<5
5 x 106 PerCb 489 ± 39 238 ± 55 140 ± 18
Primary SPb recipients that receive:
5 x 101 SP' 639 <5 645
5 x 106 Per C' 736 ± 174 317 ± 157 326 ± 126
Primary Per C' recipientst that receive:
5 x 106 PerCb 1,117 ± 141 882 ± 276 <5
Primary PerCb recipients that receive:
5 x 106 PerC' 977 ± 32 <5 780 ± 10
BALB/c control 1,013 820 <5
C.B-17 control 849 <5 STD
Table 11. Injection Route
SCID recipientst of:
Determines B Cell Dominance
Times
Early After Transfer
Serum
Total IgM
IgM Levels'
IgM' IgMb
/Ug1ml
Per C'(i.v.) + SPb(i.p.) 2 1,257 ± 201 1,277 ± 277 <5
10 926 ± 177 951 ± 285 <5
Per C'(i.p) + Spb(i.v.) 2 422 ± 7 37±3 215±9
10 642 ± 114 321 ± 125 48 ± 16
Per C'(i.v.) + Spb(i.v .) 2 1,171 ± 112 956 ± 16 28 t 1
10 993 ± 403 1,015 ± 484 <5
Per C'(i.p) + Spb(i.p.) 2 272 ± 21 154±25 22±2
10 586 ± 169 444 ± 210 <5
BALB/c control 908 830 <5
C.B-17 control 724 <5 STDselective survival of certain long-lived lymphoid subsets, and
potential contributions by endogenous SCID NK cells (27)
to the survival or function of donor lymphocytes. Despite
these considerations, the results presented in this paper fur-
ther our understanding of B lymphocyte function and lon-
gevity, and document potentially important regulatory in-
teractions between B cells.
The main findings presented in this paper are that feed-
back inhibition ofspontaneous and antigen-induced IgM secre-
tion can be mediated by B cellsthat exist in higher frequency
in the PerC as compared with the SP. In co-transfer ofPerC
and SP B cells from allotype-disparate donors, this feedback
inhibition is manifest as a failure of the IgM . allotype of the
SP donor to be detected in the serum of SCID recipients.
B cells from PerC can also exert feedback inhibition on
allotype-mismatched PerC B cells transferred subsequently
to the same SCID recipients. Feedback inhibition or B
cell-mediated allotype dominance does not appear to require
T lymphocytes. B cells capable of mediating allotype domi-
nance are found both in the PerC and the spleen of normal
BALB/c or C.B-17 donors (albeit at different frequencies),
but are absent or substantially reduced in BALB.xid donors.
Feedback inhibition probably affects primarily Ig synthesis
or secretion, since significant numbers of B cells expressing
the "suppressed" allotype can be detected in the spleens, but
not in the peritoneal cavity, ofallotype chimeric SCID mice.
However, the possibility that a small but important fraction
ofB cells of the "suppressed" allotype are missing in the PerC
+ SP B cell chimeras cannot be excluded. Independent but
simultaneous transfer of PerC cells to the peritoneal cavity
(intraperitoneal injection) and SP cells to the spleen (intrave-
nous injection) leads to a delayed onset ofallotype dominance
by the PerC cells, suggesting that feedback inhibition is not
mediated by a secreted product such as Ig, and instead may
require either cell contact or close proximity. Sera from SCID
recipients showing allotype dominance do not transfer dom-
inance to secondary recipients (data not shown), whereas sec-
ondary transfer ofB cells does maintain allotype dominance
(Table 7).
The B cells responsible for allotype dominance in our ex-
periments share several characteristics with the CD5' (and
their CD5' "sisters") B cell population (7, 8): (a) they are
present in the spleen at a lower frequency than in the perito-
neal cavity; (b) they are enriched in "large" B cell fractions;
(c) they preferentially repopulate the peritoneal cavity; (d) they
are long-lived; and (e) they appear to account for the majority
of spontaneous IgM . secretion, as has been noted previously
(8). As noted in previous studies (Riggs, J.E., et al., manu-
script submitted for publication), CD5 expression is not a
reliable marker of this population following transfer to SCID
recipients, but the general concept that a CD5-like subset
with high representation in PerC is the primary mediator
offeedback inhibition is attractive. Feedback inhibition medi-
ated by CD5+ B cells has recently been reported by Lalor
et al. (18) under different experimental conditions. An anti-
IgMb mAb was used to temporarily block development of
B cells in C.B-17 neonatal mice; subsequent injection ofsorted
Ly-1 + BALB/c B cells led to a long-term decrease in both
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endogenous Ly-1+ B cells and IgM of host origin. In con-
trast to our results, however, the reduction in cell numbers
was more impressive than the reduction in IgMb levels.
Raveche et al. (28) also have reported that hyperdiploid
CD5+ B cells from old NZB mice downregulate'both en-
dogenous B cell numbers and IgM secretion in unirradiated
young (NZB x DBA/2) Fl recipients. A similar type of
feedback inhibition has been postulated to be involved in mul-
tiplemyeloma patients, although the mechanism of this in-
hibition remains to be elucidated (29). The finding that mice
with the xid mutation have reduced numbers of CD5 B cells
and accept long-term grafts of normal B cellswithout prior
irradiation (8, 30) is also consistent with a role for CD5 B
cells in feedback inhibition.
The allotype dominance seen in the co-transfer of PerC
and SP B cells could have alternative explanations that do
not involve feedback inhibition. The simultaneous transfer
of two B cell populations to a SCID recipient creates a com-
petition in many ways analogous to the competition of two
species for a restricted habitat. The more rapid expansion of
one population, even if their advantage is small, may lead
to the extinction of the other population. Many observations
in our experiments are consistent with a growth advantage
of PerC B cells, but one experiment suggests that this expla-
nation may be insufficient. The sequential transfer of SP cells
followed by PerC cells led to a replacement of the originally
engrafted SP B cellsby PerC B cells, with a transition phase
when both allotypes are expressed. In contrast to this result,
the simultaneous transfer ofa 9:1 excess of SP to PerC B cells
led to a long-lived dominance of the SP B cell allotype. These
apparently conflicting results could be explained if the act
ofB cell isolation and transfer led to cell activation, such that
delayed transfer ofPerC B cells led to a competition between
activated PerC B cells and less activated (established) B cells
ofSP origin. In contrast, both populations would be subject
to activation in the simultaneous 9:1 SP/PerC transfer ex-
periment. While the simplest explanation for our results is
the competition of two populations for a limited B cell
microenvironment, these experiments do raise the question
of whether B cell allotype dominance reflects a direct com-
petition, competition in addition to feedback inhibition, or
both. Direct competition could reflect limitations in the avail-
ability ofsuitable microenvironments for B cell engraftment
(e.g., the marginal zone of spleen where CD5 B cells appear
to reside [8]) or competition for limited amounts ofcytokines
necessary for B cell differentiation. Feedback inhibition would
appear from our experiments to involve either direct cell-to-
cell contact or close proximity, and cannot be mediated by
passive transfer of serum, so it is unlikely that Ig mediates
the inhibition.
Our results do not allow resolution of the issue of inde-
pendent conventional and CD5 + B cell lineages as first pro-
posed by Hayakawa et al. (9), but they do call into question
the interpretation ofthose experiments. Iftransfer of one popu-
lation enriched for CD5 B cells can block development or
Ig synthesis by another, then an experimentin which allotype-
marked Ly-1 B cells are transferred to an irradiated recipient
and result in dominant expression of that allotype (9) doesnot necessarily coincide with the interpretation that Ly-1 B
cells represent a separate lineage. Our data do not eliminate
this possibility; we simply point out that it remains an open
issue.
The important and unresolved question is the extent to
which competition between B cell subsets influences the
normal pattern of B cell development in intact mice. CD5
B cells are prominent in neonatal life (8), yet they obviously
do not maintain that dominance in any site other than the
PerC. Nonetheless, our results imply that the first wave of
B cell differentiation could have profound effects on any B
cells that develop subsequently, and that such effects are not
necessarily mediatedby idiotypicnetworks (31). If theseeffects
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